Institute of Infection & Immunity, St George's University of London, United Kingdom.
Institute of Infection & Immunity, St George's University of London, United Kingdom.
Pharmacol Ther. 2020 Dec;216:107706. doi: 10.1016/j.pharmthera.2020.107706. Epub 2020 Oct 16.
Artemisinins are a unique class of antimalarial drugs with significant potential for drug repurposing for a wide range of diseases including cancer. Cancer is a leading cause of death globally and the majority of cancer related deaths occur in Low and Middle Income Countries (LMICs) where conventional treatment options are often limited by financial cost. Drug repurposing can significantly shorten new therapeutic discovery pathways, ensuring greater accessibility and affordability globally. Artemisinins have an excellent safety and tolerability profile as well as being affordable for deployment in Low and Middle Class Income Countries at around USD1 per daily dose. Robust, well designed clinical trials of artemisinin drug repurposing are indicated for a variety of different cancers and treatment settings.
青蒿素类药物是一类独特的抗疟药物，具有广泛的药物再利用潜力，可用于治疗包括癌症在内的多种疾病。癌症是全球主要死因，大多数癌症死亡发生在低收入和中等收入国家（LMICs），在这些国家，常规治疗选择往往受到经济成本的限制。药物再利用可以显著缩短新治疗方法的发现途径，确保在全球范围内具有更大的可及性和可负担性。青蒿素类药物具有极好的安全性和耐受性，并且在低收入和中等收入国家，其每天 1 美元左右的价格也具有可负担性。针对不同类型的癌症和治疗环境，进行强有力的、精心设计的青蒿素药物再利用临床试验是必要的。
